Sarepta Therapeutics Stock News

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus rating of Buy from the twenty-two research firms that are covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokers that have []

NEXT Financial Group Inc cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,629 shares of the biotechnology companys stock after selling 267 shares during the quarter. NEXT Financial Group Incs []

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Pinnacle Associates Ltd. decreased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 110,026 shares of the biotechnology companys stock after selling 3,960 shares during the period. Pinnacle Associates Ltd.s holdings in Sarepta Therapeutics were worth $10,175,000 at the end of the most recent []

Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

During the last session, Sarepta Therapeutics Inc. (NASDAQ:SRPT)s traded shares were 0.41 million, with the beta value of the company hitting 1.24. At the end of the trading day, the stocks price was $80.98, reflecting an intraday gain of 2.08% or $1.65. The 52-week high for the SRPT share is $181.83, that puts it down After Sarepta Therapeutics Inc. (NASDAQ: SRPT) Surges -137.1% From Highs, What Will It Look Like? Read More »

Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players

Wall Street analysts expect that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce earnings per share (EPS) of ($1.02) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Sarepta Therapeutics earnings. The lowest EPS estimate is ($1.39) and the highest is ($0.64). Sarepta Therapeutics reported earnings per share of ($2.40) during the same []

Analysts forecast that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce earnings per share (EPS) of ($1.02) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Sarepta Therapeutics earnings, with estimates ranging from ($1.39) to ($0.64). Sarepta Therapeutics posted earnings of ($2.40) per share during the same quarter last year, which []

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CEO Douglas S. Ingram acquired 25,026 shares of the businesss stock in a transaction dated Wednesday, November 17th. The stock was purchased at an average price of $79.94 per share, with a total value of $2,000,578.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which []

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company’s head of research and development (R&D) and will continue to serve in the role of chief scientific officer. Gilmore O’Neill, M.B., M.M.Sc., who has served as head of R&D since 2018, will leave the Company at the end of November and remain in a consulting capacity until March 31, 2022.

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology (Caltech), and serves on the board of directors for Merck and on the scientific advisory board of Rubryc Therapeutics.

Sarepta Therapeutics (NASDAQ: SRPT) recently received a number of ratings updates from brokerages and research firms: 11/5/2021 Sarepta Therapeutics was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. They now have a $130.00 price target on the stock, up previously from $88.00. 11/4/2021 Sarepta Therapeutics []

Related Stocks: SRZN , ARYE , OLK , PTGX , LEGN , VSTM , KROS , SRPT , AFMD ,

The biotech stock fell a little more than $72 since its close last Friday.